Key facts
- It has raised $1.0M; the latest was Early Stage VC ($1.0M) in Dec 2024.
- Notable investors include YouNick Mint.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Onconick
- ·The full record, as it builds
Funding rounds
No funding rounds for Onconick are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Onconick
Developer of oncological therapy intended for lung cancer treatment. The company designs and thoroughly investigates the properties of an antibody-drug conjugate (ADC) for the effective therapy of lung cancer overexpressing the FGFR1 protein, enabling medical professionals with improved alternatives for cancer treatment.
- Sector
- Healthcare
- HQ
- Zlotniki, Poland
- Founded
- 2020
- Employees
- 3
- Website
- onconick.com/
- Ownership
- Privately Held (backing)
Onconick doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Onconick shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Onconick in its N-PORT filings yet. We sweep new filings monthly.